The setback leaves Lilly and partner Hanmi Pharmaceutical to weigh whether it is worth moving the Bruton's TKI forward in other indications.
The FDA has issued a complete response letter for Apricus’ topical ED drug Vitaros again, sparking a massive after-hours slump in its share price.
The takeover gives Roche ownership of the cancer software and real-world evidence that turned GV-backed Flatiron into a rising star.
Axovant CEO Hung resigned, Arcturus CSO and COO Chivukula stepped down, Celgene spinoff emerged with Bob Hariri at the reins.
Scientists at Stanford University believe stem cells can teach the immune system to recognize and attack cancer.
Roivant and Arbutus have a month to decide if they're going to set up a new company for RNA delivery.
A Celgene spinout known as Celularity with some of the biggest names in biotech and Silicon Valley has raised $250 million for its work in cancer.
Vertex Pharma now has a pair of studies backing up its new drug VX-150, suggesting it can provide opioidlike pain relief without the addiction risks.
The Swiss biotech penned a CHF 127.5 million ($138 million) deal for the human neutrophil elastase inhibitor to expand its clinical pipeline.
In this week's EuroBiotech Report, Boehringer scraps Alzheimer’s drug, Poxel lands Roivant deal, Santhera snags cystic fibrosis drug and more.